Women buying testosterone online after NHS access barriers in Wales

A woman in Wales was prescribed testosterone by her NHS GP, a hormone that some post-menopausal women find helps restore libido and energy. When she moved to a neighbouring health board area, her new GP refused to continue the prescription. She paid for a private consultation and blood tests to stabilize her levels, then filled out an online pharmacy questionnaire claiming to be a man so she could afford the hormone at a fraction of the cost. She is not alone in taking this route.

Women across Wales are posing as men to buy testosterone from online pharmacies because access through the NHS has become unpredictable and often blocked. Dr Michelle Olver, a menopause specialist, has documented cases where women self-medicating this way have reached testosterone levels up to 12 times the safe dose—risking permanent physical damage including baldness, voice deepening, and clitoral enlargement. The problem reflects a deeper fragmentation in how Wales' seven health boards approach testosterone prescribing for post-menopausal women, with some boards allowing GPs to prescribe it and others restricting it to specialists only.

Testosterone is a naturally occurring hormone that declines with age. Clinical evidence shows it can help restore sexual desire in post-menopausal women, and many women report it also improves energy and mental clarity, though a study is currently underway in Wales to verify those claims scientifically. The NHS has no licensed female testosterone product, so doctors prescribe the male formulation in much lower doses. Women are supposed to have baseline blood tests and regular monitoring to keep their levels within the female physiological range. But access depends entirely on where they live and which GP they see.

Dr Rebeccah Tomlinson, a GP who runs a menopause clinic in a hospital gynaecology department and trains other doctors in menopause care, describes the situation plainly: some physicians are reluctant to prescribe medications off-licence, and some practices have imposed total bans on testosterone prescribing to distribute workload fairly among staff. That shifts the burden to secondary care—hospital gynaecology waiting lists—creating delays that can stretch months. "It's a postcode lottery and very dependent on the practice and the clinician," Tomlinson said. "You can hit barriers along the way. It's really difficult when you might know somebody else who's going through exactly the same thing and has sailed through the process."

Each of Wales' seven health boards uses a traffic light system to categorize testosterone access. Some are red, meaning only specialists can prescribe it. Two amber options exist: one allows a GP to request specialist agreement before prescribing; the other requires the specialist to initiate and monitor the prescription under a shared care agreement with the GP. This patchwork has driven referrals sharply upward. Olver, who runs the menopause clinic at Aneurin Bevan health board, said her team has seen "a very sharp increase in testosterone referrals from primary care" and has now established a dedicated testosterone clinic to try to meet demand.

Emma Thomas, 59, co-founded Menopals Cardiff and Vale, a menopause support group. She hears constantly from members struggling to access testosterone on the NHS—GPs telling them it is unnecessary, surgeries refusing to prescribe it. Thomas herself experienced a profound shift at 47, moving from being "a really sociable, happy person" to feeling "quite insecure, paranoid, low in mood." She lost what she calls her joy. Hormone replacement therapy made a difference within ten days. Once her HRT was stable, her GP prescribed testosterone. It took six months to feel the effect, but she describes it as "the final piece of the puzzle." She now feels like her old self, she said, with "a zest for life."

Other women report mixed experiences. Emma Jones, 57, noticed her energy increase within a week of starting testosterone but also felt "jittery and on edge." She laughed describing the sensation: "I felt like I'd changed into the body of an 18-year-old, thinking about sex from the moment I woke up." Both women and specialists agree testosterone is not a cure-all. Studies show about 60 percent of women experience improved libido. Olver emphasizes that many reasons exist for low sexual desire—external factors, anatomical issues—and that proper counselling and monitoring are essential. "We want to maintain women in female physiological range for testosterone," she said. "We don't want them to have sky-high levels."

A licensed female testosterone product called Androfeme has been available in other countries for years and through private clinics across the UK. It recently achieved a UK licence but now awaits appraisal by NICE to determine cost-effectiveness for NHS use. The female product costs the NHS around £100 per prescription; the male formulation costs £30. That price difference, combined with the licensing gap, has contributed to the current disparity. The Welsh government said all health boards are expected to provide individualised care and adhere to NICE guidelines on menopause management, and that it expects health boards to conform to any NICE recommendations on testosterone prescribing once guidance is published. Until then, women continue to navigate a fractured system, some turning to unregulated online sources where dosing goes unchecked and the risks accumulate unseen.